Cargando…

Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes

BACKGROUND: In contrast to Western population, glucagon-like peptide-1 (GLP-1) levels are preserved in some East Asian population with type 2 diabetes (T2D), explaining why dipeptidyl peptidase-IV (DPP-IV) inhibitors are more effective in East Asians. We assessed whether differences in endogenous GL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chong, Shiau Chin, Sukor, Norlela, Robert, Sarah Anne, Ng, Kim Fong, Kamaruddin, Nor Azmi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576919/ https://www.ncbi.nlm.nih.gov/pubmed/36267570 http://dx.doi.org/10.3389/fendo.2022.1012412

Ejemplares similares

Fasting and stimulated glucagon-like peptide-1 exhibit a compensatory adaptive response in diabetes and pre-diabetes states: A multi-ethnic comparative study
por: Chong, Shiau Chin, et al.
Publicado: (2022)

Editorial: Expanding spectrum of primary aldosteronism: exploring new grounds
por: Sukor, Norlela, et al.
Publicado: (2023)

Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis
por: Wan Azman, Siti Sanaa, et al.
Publicado: (2022)

Prevalence and Histopathological Characteristics of KCNJ5 Mutant Aldosterone-Producing Adenomas in a Multi-Ethnic Malaysian Cohort
por: Mohideen, Syahirah Kaja, et al.
Publicado: (2019)

Study protocol to develop a core outcome set for thyroid dysfunction to bridge the unmet needs of patient-centred care
por: Ooi, Cheow Peng, et al.
Publicado: (2021)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
por: Stenlid, Rasmus, et al.
Publicado: (2023)

A Case of Retroperitoneal Liposarcoma Mimicking an Adrenocortical Carcinoma
por: Kang, Waye, et al.
Publicado: (2019)

Primary aldosteronism and obstructive sleep apnea: What do we know thus far?
por: Loh, Huai Heng, et al.
Publicado: (2022)

Profiles and Factors Associated with Poor Glycemic Control Among Inpatients with Diabetes Mellitus Type 2 as a Primary Diagnosis in a Teaching Hospital
por: Ismail, Aniza, et al.
Publicado: (2016)

Editorial: Adrenal related hypertension: from bench to bedside
por: Sukor, Norlela, et al.
Publicado: (2023)

Fluconazole as a Safe and Effective Alternative to Ketoconazole in Controlling Hypercortisolism of Recurrent Cushing’s Disease: A Case Report
por: Teng Chai, Shu, et al.
Publicado: (2018)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
por: Gilbert, Matthew P., et al.
Publicado: (2020)

Case Report: Severe Hypernatremia From Ingestion of One's Own Urine
por: Kang, Waye Hann, et al.
Publicado: (2022)

MON-318 Selective ACTH Sampling in Localizing Source of ACTH in Von Hippel Lindau Disease with Pancreatic Neuroendocrine Tumour and Renal Cell Carcinoma
por: Singarayar, Carolina, et al.
Publicado: (2019)

SUN-711 Association of Single Nucleotide Polymorphisms of CYP11B2, CYP11B1 and CYP17A1 with Primary Aldosteronism in a Multi-Ethnic Malaysian Cohort
por: Azam, Afifah, et al.
Publicado: (2020)

GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
por: Brunton, S
Publicado: (2014)

The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study
por: Al-Mashhadi, Zheer Kejlberg, et al.
Publicado: (2022)

A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity
por: Chhabria, Srishti, et al.
Publicado: (2022)

Effects of Sambiloto (Andrographis paniculata) on GLP-1 and DPP-4 Concentrations between Normal and Prediabetic Subjects: A Crossover Study
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2022)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Inhibition of DPP-IV Activity and Stimulation of GLP-1 Release by Gastrointestinally Digested Black Soldier Fly Prepupae
por: Luparelli, Anna Valentina, et al.
Publicado: (2023)

Response to COVID-19 and diabetes: Can DPP4 inhibition play a role? – GLP-1 might play one too
por: Morin, Nathaniel
Publicado: (2020)

The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism
por: Pan, Xiaohui, et al.
Publicado: (2020)

Estrogen Receptors in Nonfunctioning Pituitary Neuroendocrine Tumors: Review on Expression and Gonadotroph Functions
por: Haydar Ali Tajuddin, Amalina, et al.
Publicado: (2020)

DPP-4 Inhibition and the Path to Clinical Proof
por: Ahrén, Bo
Publicado: (2019)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
por: Meier, Juris J., et al.
Publicado: (2021)

Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System
por: Janssens, Jonathan, et al.
Publicado: (2014)

Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study
por: Sanada, Junpei, et al.
Publicado: (2021)

Editorial: Prediabetes and endocrine function
por: Khathi, Andile, et al.
Publicado: (2023)

Effects of sacubitril/valsartan on both metabolic parameters and insulin resistance in prediabetic non-obese patients with heart failure and reduced ejection fraction
por: Cloro, Cosima, et al.
Publicado: (2022)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

[Gly²]-GLP-2, But Not Glucagon or [D-Ala²]-GLP-1, Controls Collagen Crosslinking in Murine Osteoblast Cultures
por: Mieczkowska, Aleksandra, et al.
Publicado: (2021)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

MON-LB129 A Pilot Genome Wide Association Study (GWAS) on Primary Aldosteronism Patients in a Multi-Ethnic Malaysian Cohort
por: Azizan, Elena AB, et al.
Publicado: (2020)

PSUN14 Elucidating Effect of Modulating Aldosterone Synthesis on Cell Fate in Human Adrenal Cells
por: Long, Kha Chin, et al.
Publicado: (2022)

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
por: Deacon, Carolyn F.
Publicado: (2019)

Underestimated Prediabetic Biomarkers: Are We Blind to Their Strategy?
por: Luís, Carla, et al.
Publicado: (2022)

Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus
por: Kim, Sun Woo
Publicado: (2010)

The central GLP-1: implications for food and drug reward
por: Skibicka, Karolina P.
Publicado: (2013)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j373pb6gukptd07vujn2je4v9b